Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
122 hedge funds and large institutions have $532M invested in Array Biopharma Inc in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 41 increasing their positions, 42 reducing their positions, and 25 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 42
7% less capital invested
Capital invested by funds: $571M → $532M (-$38.6M)
15% less funds holding
Funds holding: 143 → 122 (-21)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
66% less call options, than puts
Call options by funds: $1.61M | Put options by funds: $4.79M
76% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$4.89M |
| 2 |
DM
Deerfield Management
New York
|
+$4.88M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$4.7M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.37M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.77M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$2.52M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.42M |
| 4 |
QF
QVT Financial
New York
|
-$1.9M |
| 5 |
Renaissance Technologies
New York
|
-$1.82M |
ARRY Hedge Fund Activity: Q1 2014 in Review
122 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2014, worth a combined $532M — down 6.8% from $571M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ARRY and 6 opened new positions — a net loss of 19 holders — while 42 trimmed existing stakes and 41 added.
The largest buyer was OrbiMed, adding an estimated $4.89M. The largest seller was Millennium Management, cutting an estimated $2.77M.
- 122 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2014, down from 143 in Q4 2013.
- Funds reported $532M of Array Biopharma Inc stock for Q1 2014, down 6.8% quarter-over-quarter.
- 6 funds opened new Array Biopharma Inc positions in Q1 2014 and 25 closed out, a net change of -19 holders.
- The largest Array Biopharma Inc buyer in Q1 2014 was OrbiMed, an estimated $4.89M added.
- The largest Array Biopharma Inc seller in Q1 2014 was Millennium Management, an estimated $2.77M sold.
Based on aggregated 13F filings for Q1 2014.